PTHS · Pelthos Therapeutics Inc. · Debt
$19.59
+0.89 (+4.76%)
At close · Oct 22
Return incl. dividend (before tax)
Going-concern doubt
— cleared May 14, 2026
The latest filing states the doubt was alleviated.
“in prior periods, management disclosed substantial doubt about the Company's ability to continue as a going concern. The conditions and events that previously raised substantial doubt have been alleviated by management's plans and actions.”View the 10-Q filed May 14, 2026
Market Cap
$75.00M
Shares
3.83M
Volume · Oct 22
79.8K
Avg daily vol (3M)
61.99K
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 645,000 | 10-Q filed 2026-08-13 |
| Noncurrent convertible debt | 2026-06-30 | USD 43,321,000 | 10-Q filed 2026-08-13 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 2,550,000 | 10-Q filed 2026-08-13 |
| Noncurrent secured debt | 2026-06-30 | USD 26,593,000 | 10-Q filed 2026-08-13 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.